title: Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication.
abstract: Chronic hepatitis B patients with low pre-treatment HBeAg (and HBV-DNA) levels are more likely to respond to interferon-alpha therapy. In retrospect, this low level of HBeAg may have been reached just before the start of therapy. Pre-treatment changes in HBeAg levels were studied in 121 patients undergoing interferon-alpha 2B therapy. HBeAg was monitored by the AxSYM HBe 2.0 Quantitative (Abbott Laboratories) and HBV-DNA by liquid hybridisation (Abbott Laboratories). At the end of treatment (week 16) 24 patients had responded (HBeAg and HBV-DNA below the level of detection). Response was significantly (P = 0.007) related to a decrease in HBeAg level before the start of therapy. Eight of the 24 (33%) responding patients exhibited a > 50% decrease in HBeAg level just before the start of therapy compared to 7 of the 97 (7%) non-responding patients. The geometric mean titre of HBeAg decreased significantly (P < 0.005; 8-week period before start) among responding patients (271 ( 98 PEI U/ml) in contrast to non-responding patients (737 ( 724 PEI U/ml). Planning the start of interferon treatment just after a spontaneous decrease in HBV replication may increase the response rate for interferon-alpha therapy.
authors.affiliation: Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands. Heijtink@viro.fgg.eur.nl
authors.forename: R A
authors.initials: RA
authors.lastname: Heijtink
authors.forename: H L
authors.initials: HL
authors.lastname: Janssen
authors.forename: W C
authors.initials: WC
authors.lastname: Hop
authors.forename: A D
authors.initials: AD
authors.lastname: Osterhaus
authors.forename: S W
authors.initials: SW
authors.lastname: Schalm
mesh_terms: D004279:DNA, Viral / Q000097:blood; D004334:Drug Administration Schedule; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014779:Virus Replication
chemical_list: D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins